This is a followup to my posting only the latest health news and research findings in the press on the causes of breast cancer. The latest information on breast cancer research stated that both pollution in the environment and the use of synthetic hormones in hormone replacement therapy are the causes of breast cancer. It has not been proven that natural bioidentical hormone therapy causes breast cancer. I stated that it has always been suspected that pollution in the environment causes not only breast cancer but other types of cancer and birth defects. But now, the idea of pollution as a cause of breast cancer has now gone mainstream. It would appear that both synthetic hormone replacement therapy, environmental pollution and diet are directly related to breast cancer.
The following article discusses the link between breast cancer and pollution in the environment comes from the womensenews.org website.
Breast Cancer Link to Environment Goes Mainstream
A mammogram image of the breast
“When she looks at her suburban street, Geri Barish sees cancer. She believes it’s under her feet, in the soil that came from landfill and has been sprayed with pesticides. She believes it’s overhead, in the electric transformers that hang from telephone poles on her quiet cul-de-sac.
“Pollution from these sources may explain the cancer that killed my mother, my son and too many of my neighbors,” said Barish, of Hewlett, N.Y., a middle-income community at the heart of a dense cluster of cancer cases. “It may also explain why I’ve had to battle breast cancer three separate times myself.”
Back in 1990, when Barish and some female neighbors founded the Long Island Breast Cancer Action Coalition, their goal–to raise awareness of the link between pollutants and high rates of cancer in their area–was considered politically fringe.
Twenty years down the line, presidential advisors, lawmakers and the largest breast cancer research group in the country are all simultaneously pulling the issue to the center of the political stage.
A big sign of this change will occur July 6-8, when Susan G. Komen for the Cure–the world’s largest breast cancer organization–and the Institute of Medicine, a Washington-based health policy group, conduct a joint meeting in San Francisco on environmental toxins and breast cancer.
“The public is invited to observe our upcoming meeting, which will include presentations from leading breast cancer researchers and organizations,” said Dr. Amelie Ramirez of Komen’s scientific advisory board. “We believe this meeting is very important and expect it to generate much collaborative input.”
In the advocacy realm, this represents something of a seismic shift by the Dallas-based Susan G. Komen for the Cure, which has long focused on breast cancer treatment, rather than prevention.
But on May 20, the group, which has invested nearly $1.5 billion to fight breast cancer since its inception in 1982, said it was devoting $1.25 million to a year-long Institute of Medicine study on cancer and the environment.”
Recently the latest health news and research findings in the press have revealed articles on the causes of breast cancer. The latest news in breast cancer research states that both pollution in the environment and the use of synthetic hormones in hormone replacement therapy are the causes of breast cancer. Really, this isn’t news at all because in 2002, the Womens Health Initiative found that synthetic hormone use increased the risk of deadly breast cancer among other health risks, and it has always been suspected that pollution in the environment causes not only breast cancer but other types of cancer and birth defects.
The following article, speaks to the issue of the use of synthetic hormones in hormone replacement therapy are for my readers concerned about breast cancer news and research. This article on Hormone Replacement Therapy as a cause of breast cancer comes from the NYDailyNews.com.
Hormone replacement therapy caused more advanced, deadlier breast cancer: AMA
Women who took hormone replacement pills had more advanced breast cancers and were more likely to die from them than women who took a dummy pill, raising new concerns about the commonly prescribed drugs, U.S. researchers said on Tuesday.
The study, published in the Journal of the American Medical Association, is the first to report more breast cancer deaths among women taking hormone replacement therapy. And it contradicts prior studies that suggest women taking the drugs had less aggressive, easier-to-treat breast cancers.
HRT as a cause of breast cancer
“As opposed to the prevailing thought of two years ago, that cancers associated with estrogen plus progesterone would be favorable and not much of a problem, we are actually showing they are associated with an increased risk of death from breast cancer,” Dr. Rowan Chlebowski of the Los Angeles Biomedical Research Institute, who led the study, said in a telephone interview.
The findings include 11 years of follow-up from the Women’s Health Initiative study, which in 2002 found women who took estrogen plus progestins (synthetic progesterone) for five years had higher rates of ovarian cancer, breast cancer, strokes and other health problems.
Sales of U.S. market leader Wyeth’s combined estrogen plus progesterone pill Prempro have fallen by about 50 percent since 2001 to around $1 billion a year. Wyeth is now owned by Pfizer.
Chlebowski’s team analyzed data on the more than 12,000 women in the study. They found twice as many taking HRT died from breast cancer — 2.6 per 10,000 per year versus 1.3 per 10,000 women per year — compared to women who took a placebo.
Nearly 24 percent of the breast cancer patients who took HRT had tumors that had spread to the lymph notes, compared with 16 percent of women taking placebos.
“All the scary cancers with unfavorable prognoses were also increased,” Chlebowski said, citing increases in aggressive forms of breast cancer, and not just estrogen-fed cancers that are easier to treat.
“And then for the first time we show deaths from breast cancer are significantly increased as well,” he said.
Pfizer said in a statement the company stands behind Prempro’s current labeling, which advises doctors to prescribe the drug at the lowest effective dose for the shortest possible period of time.
But even that may be risky, suggests Dr. Peter Bach of Memorial Sloan-Kettering Cancer Center in New York, who wrote a commentary in the same journal.
Doctors can only be guessing that taking the pills at a lower dose and for a shorter time would be less harmful, Bach said in a telephone interview.
Doctors “should be aware that this approach has not been proven in rigorous clinical trials,” Bach wrote.
“As a science-based company, we take this analysis seriously,” Pfizer said in a statement.
“It is important to view the data in the full context of both the symptoms of menopause as well as the extensive body of information — developed over more than 60 years — on the known benefits and risks of hormone therapy.”
Doctors note that the average age of the women in the Women’s Health Initiative study was 63, several years past menopause, and say the findings may not apply to women taking other forms of HRT (such as bioidentical hormones), or to those starting HRT immediately at the time of menopause.
According to a recent article in the BBC, the latest medical research has finally been able to answer the questions as to why some women do not respond to the breast cancer drug Tamoxifen. This discovery will lead to hope in the women who have breast cancer and are not successfully responding to treatment. This medical research was recently published in the Cancer Research Journal.
Scientists find why tamoxifen fails some breast cancers
“UK scientists say they have discovered why some women fail respond to breast cancer treatment, and it is a gene error they believe they can fix. Tamoxifen is given to most women diagnosed with breast cancer to prevent the cancer returning.
But not all women respond to the drug – experts estimate a third get no benefit. The work in the journal Cancer Research suggests the problem is too much of a gene called FGFR1. This discovery could lead to new treatments for these women as scientists “switch off” the action of FGFR1, enabling Tamoxifen to work.
The team of scientists in the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research have already shown this is possible in the lab.
They introduced a drug which “switched off” the action of FGFR1.
Once FGFR1 was stopped, hormone-based treatments like Tamoxifen could get back to work in destroying cancer cells, they found.
The researchers believe this could ultimately help thousands of women each year.
They say one in 10 breast cancer patients has too much of the FGFR1 gene.
Dr Nick Turner, who led the research, said: “Understanding how this gene can cause Tamoxifen resistance reveals a new drug target for treating breast cancers in patients who would otherwise have a poor outcome.
“There are a number of drugs in development that stop FGFR1 working, and clinical studies are investigating whether these drugs work against cancers with too many copies of this gene.
“The next step is to set up a clinical trial to see whether a drug that blocks the action of this gene can counteract hormone therapy resistance in breast cancer patients.
“If these trials confirm our lab work we could be on the verge of a potentially exciting new treatment for breast cancer.” Dr Lesley Walker of Cancer Research UK, the charity which helped fund the work, said: “Cracking the problem of resistance to treatments such as Tamoxifen would be a major advance in treating breast cancer.” Breast cancer is the most common cancer in the UK affecting more than 45,500 women each year.
Tamoxifen blocks the female sex hormone estrogen that fuels the growth of some breast tumours. ”
Source: BBC News
